B cells resistant to CD20 monoclonal antibodies display specific alterations in gene expression profile.

LEDEREROVÁ, Aneta, Veronika KOZLOVÁ, Viera VAKULOVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. B cells resistant to CD20 monoclonal antibodies display specific alterations in gene expression profile. In 22nd congress of EHA, Madrid, Španělsko, červen 2017 in Haematologica (2017). 2017.

Basic information

• Original name: B cells resistant to CD20 monoclonal antibodies display specific alterations in gene expression profile.
• Authors: LEDEREROVÁ, Aneta (203 Czech Republic, belonging to the institution), Veronika KOZLOVÁ (203 Czech Republic, belonging to the institution), Viera VAKULOVÁ (703 Slovakia, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution) and Michal ŠMÍDA (203 Czech Republic, belonging to the institution).
• Edition: 22nd congress of EHA, Madrid, Španělsko, červen 2017 in Haematologica (2017), 2017.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 30403 Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being
• Confidentiality degree: is not subject to a state or trade secret
• RIV identification code: RIV/00216224:14740/17:00095699
• Organization unit: Central European Institute of Technology
• Keywords in English: CD20; monoclonal; B cells
• Tags: rivok

Abstract

B cells resistant to CD20 monoclonal antibodies display specific alterations in gene expression profile.B cells resistant to CD20 monoclonal antibodies display specific alterations in gene expression profile.

Links

• LQ1601, research and development project: Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

• MUNI/A/1106/2016, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IV (Acronym: VýDiTeHeMA IV)

Investor: Masaryk University, Category A

• NV15-33561A, research and development project: Name: Rezistence na léčbu monoklonálními protilátkami u B-CLL a B-lymfomů: příčiny vzniku a potenciální intervenční strategie